» Articles » PMID: 24733924

Prevention of Influenza by Targeting Host Receptors Using Engineered Proteins

Overview
Specialty Science
Date 2014 Apr 16
PMID 24733924
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

There is a need for new approaches for the control of influenza given the burden caused by annual seasonal outbreaks, the emergence of viruses with pandemic potential, and the development of resistance to current antiviral drugs. We show that multivalent biologics, engineered using carbohydrate-binding modules specific for sialic acid, mask the cell-surface receptor recognized by the influenza virus and protect mice from a lethal challenge with 2009 pandemic H1N1 influenza virus. The most promising biologic protects mice when given as a single 1-μg intranasal dose 7 d in advance of viral challenge. There also is sufficient virus replication to establish an immune response, potentially protecting the animal from future exposure to the virus. Furthermore, the biologics appear to stimulate inflammatory mediators, and this stimulation may contribute to their protective ability. Our results suggest that this host-targeted approach could provide a front-line prophylactic that has the potential to protect against any current and future influenza virus and possibly against other respiratory pathogens that use sialic acid as a receptor.

Citing Articles

Advax-SM™-Adjuvanted COBRA (H1/H3) Hemagglutinin Influenza Vaccines.

Sanchez P, Andre G, Antipov A, Petrovsky N, Ross T Vaccines (Basel). 2024; 12(5).

PMID: 38793706 PMC: 11125990. DOI: 10.3390/vaccines12050455.


Sialic acids in infection and their potential use in detection and protection against pathogens.

Dedola S, Ahmadipour S, de Andrade P, Baker A, Boshra A, Chessa S RSC Chem Biol. 2024; 5(3):167-188.

PMID: 38456038 PMC: 10915975. DOI: 10.1039/d3cb00155e.


Co-infection of the respiratory epithelium, scene of complex functional interactions between viral, bacterial, and human neuraminidases.

Escuret V, Terrier O Front Microbiol. 2023; 14:1137336.

PMID: 37213507 PMC: 10192862. DOI: 10.3389/fmicb.2023.1137336.


Use of a Preclinical Natural Transmission Model to Study Antiviral Effects of a Carbohydrate-Binding Module Therapy against SARS-CoV-2 in Hamsters.

Knott D, Fell R, Potter J, Yuille S, Salguero F, Graham V Viruses. 2023; 15(3).

PMID: 36992434 PMC: 10058511. DOI: 10.3390/v15030725.


Efficient TurboID-based proximity labelling method for identifying terminal sialic acid glycosylation in living cells.

Liu W, Long Y, Bao Y, Li Y, Deng M, Yang X Acta Biochim Biophys Sin (Shanghai). 2023; 54(12):1841-1853.

PMID: 36789692 PMC: 10157534. DOI: 10.3724/abbs.2022184.


References
1.
Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W . Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013; 368(20):1888-97. DOI: 10.1056/NEJMoa1304459. View

2.
Osterhaus A, Fouchier R, Rimmelzwaan G . Towards universal influenza vaccines?. Philos Trans R Soc Lond B Biol Sci. 2011; 366(1579):2766-73. PMC: 3146782. DOI: 10.1098/rstb.2011.0102. View

3.
Xu G, Li X, Andrew P, Taylor G . Structure of the catalytic domain of Streptococcus pneumoniae sialidase NanA. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008; 64(Pt 9):772-5. PMC: 2531273. DOI: 10.1107/S1744309108024044. View

4.
Malakhov M, Aschenbrenner L, Smee D, Wandersee M, Sidwell R, Gubareva L . Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother. 2006; 50(4):1470-9. PMC: 1426979. DOI: 10.1128/AAC.50.4.1470-1479.2006. View

5.
Cantor J, Yoo T, Dixit A, Iverson B, Forsthuber T, Georgiou G . Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc Natl Acad Sci U S A. 2011; 108(4):1272-7. PMC: 3029727. DOI: 10.1073/pnas.1014739108. View